Latest news with #OryzonGenomics
Yahoo
23-06-2025
- Health
- Yahoo
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
PORTICO-2 designed to validate vafidemstat's efficacy in reducing aggression in BPD patients Primary endpoint: STAXI-2 Trait Anger (patient-reported) Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) (clinician-rated) Additional secondary endpoints will assess global clinical improvement Protocol finalized following FDA guidance and input from leading US psychiatry experts Upcoming KOL webinar to discuss trial design and the urgent medical need in BPD MADRID and CAMBRIDGE, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol for its Phase III PORTICO-2 trial to the U.S. Food and Drug Administration (FDA) to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD). The PORTICO-2 trial builds upon the encouraging results observed in the previous PORTICO Phase IIb study, where vafidemstat demonstrated significant and clinically meaningful reductions in secondary endpoints measuring aggression and overall BPD improvement. Aggression is a key symptom domain in BPD that currently represents a major unmet medical need and will be the primary endpoint in PORTICO-2. Vafidemstat, an orally active LSD1 inhibitor with a novel epigenetic mechanism of action, has shown a favorable safety and tolerability profile across multiple clinical studies. "The submission of PORTICO-2 to the FDA marks a major step forward for Oryzon and for the field of neuropsychiatry of personality disorders," said Carlos Buesa, Chief Executive Officer of Oryzon. "Borderline Personality Disorder is a highly disabling condition with no approved pharmacological treatments. With its novel epigenetic mechanism, vafidemstat has the potential to become the first targeted therapy specifically addressing aggression and overall improvement in BPD, offering real hope for patients and clinicians confronting this serious disorder. Vafidemstat has also the potential to manage aggression in other neurodevelopmental and neurodegenerative disorders, and we are planning to explore it in a new trial in aggression in ASD." The Phase III protocol was developed through multiple interactions and constructive exchanges with the FDA. Its final design was further refined with the scientific contribution of internationally recognized psychiatric experts, including Dr. Alan Schatzberg (Stanford University), Dr. Eric Hollander (Albert Einstein Medical School), Dr. Emil Coccaro (Ohio State University Wexner Medical Center), and Dr. Sarah Fineberg (Yale University). PORTICO-2 will employ two clinical outcome measures for aggression: the STAXI-2 Trait Anger scale (patient-reported) as the primary endpoint, and the Overt Aggression Scale-Modified (OAS-M) (clinician-rated) as key secondary endpoint. Additional secondary endpoints will evaluate broader clinical improvements in BPD symptomatology and quality of life. A dedicated Key Opinion Leader (KOL) webinar is planned in the coming weeks to discuss the PORTICO-2 study design, the substantial unmet medical need in BPD, and the role of aggression as a clinical target. Details will be announced in a further communication. PORTICO-2 will be a randomized, double-blind, placebo-controlled, multi-center study to assess both the efficacy and safety of vafidemstat in BPD patients, and aims to randomize 350 patients. BPD affects approximately 1-2% of the general population and is characterized by pervasive emotional instability, impulsivity, interpersonal dysfunction, unstable self-image and frequent episodes of aggression and self-harm. More than 75% of BPD patients attempt suicide, and the rate of completed suicide has been estimated to be approximately 10%, 50-times higher than in the general population. Currently, there are no FDA-approved medications specifically indicated for the treatment of BPD, underscoring the urgent need for novel therapeutic approaches. Additional exploratory data from earlier Phase IIa studies suggest that vafidemstat may also reduce aggression in other patient populations, including Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), and Alzheimer's Disease (AD). The company is planning to explore this further in a new trial in aggression in ASD to be conducted within the activities of the Med4Cure IPCEI-EU Grant. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate, ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit About Vafidemstat Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer's disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong, and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed two Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders (REIMAGINE, see Ferrer et al, Psychiatry & Clin Neurosci, 2025, and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive clinical results reported in both. Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL trial in patients with Mild to Moderate AD, where a significant reduction of the inflammatory biomarker YKL40 was observed after 6 and 12 months of treatment, and the pilot, small-scale SATEEN trial in Relapse-Remitting and Secondary Progressive MS, where anti-inflammatory activity was also observed. Vafidemstat has also been tested in a Phase II in severe Covid-19 patients (ESCAPE) assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection, where it showed significant anti-inflammatory effects in severe Covid-19 patients. Vafidemstat is currently advancing as a Phase III-ready asset in Borderline Personality disorder (BPD) following completion of the global, randomized, double blind Phase IIb PORTICO trial (final data presented at ECNP-2024). Following receipt of the minutes from the End-of-Phase II meeting with the FDA to discuss PORTICO's results, the company announced plans to move forward with a Phase III PORTICO-2 trial in agitation/aggression in BPD (PhIII protocol submitted to FDA). Vafidemstat is also being investigated in a double-blind, randomized, placebo-controlled Phase IIb trial in negative symptoms of schizophrenia (EVOLUTION trial, recruitment ongoing). The company is also deploying a CNS precision medicine approach with vafidemstat in genetically defined patient subpopulations of certain CNS disorders, as well as in neurodevelopmental syndromes, and is evaluating the feasibility of conducting clinical trials in autistic conditions like Fragile X syndrome and Phelan-McDermid syndrome. FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.. Spain Oryzon IR & Media, Europe & US Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid Atrevia Chief BD Officer LifeSci Advisors, LLC +34 91 564 07 25 +34 673 33 97 65 +34 93 515 1313 +41 78 680 05 38 pcobo@ mcordera@ etorrell@ svonderweid@
Yahoo
05-06-2025
- Business
- Yahoo
High Growth Tech Stocks in Europe to Watch for Potential Expansion
The European market has shown resilience with the pan-European STOXX Europe 600 Index ending 0.65% higher, buoyed by easing trade tensions and slowing inflation in key economies, which may prompt further monetary easing by the European Central Bank. In this context of potential expansion and shifting economic policies, high-growth tech stocks become particularly intriguing for investors seeking opportunities that align with evolving market dynamics and technological advancements. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 228 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €226.34 million. Operations: Oryzon Genomics specializes in discovering and developing epigenetics-based therapeutics targeting cancer and CNS disorders. Oryzon Genomics, a trailblazer in epigenetic therapies, is making significant strides with an impressive 49.3% annual revenue growth forecast. Despite its current unprofitability, the company's strategic focus on R&D (13.26 million EUR allocated to the VANDAM project) underscores its commitment to addressing rare neurodevelopmental disorders and neuroendocrine tumors through precision medicine. The recent 15 million EUR grant for this project enhances Oryzon's potential in pioneering treatments that could revolutionize patient care in these underserved areas. Additionally, their involvement in high-profile clinical trials like the Phase I/II trial of iadademstat for small cell lung cancer further exemplifies their innovative approach within the biotech sector. With expected profitability and earnings growth of 50.17% per annum over the next three years, Oryzon is positioned to leverage its scientific advancements into commercial success. Click to explore a detailed breakdown of our findings in Oryzon Genomics' health report. Explore historical data to track Oryzon Genomics' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Atea ASA is a leading provider of IT infrastructure and related solutions for businesses and public sector organizations across the Nordic countries and Baltic regions, with a market capitalization of NOK16.73 billion. Operations: Atea ASA generates revenue primarily from its operations in Norway, Sweden, Denmark, Finland, and the Baltics. The highest revenue contribution comes from Sweden at NOK13.06 billion, followed by Norway at NOK9 billion. Group Shared Services account for NOK10.81 billion in costs. Atea's strategic emphasis on R&D, with a notable 13% of its revenue directed towards innovation, underpins its robust position in the European tech landscape. Despite a challenging year with earnings growth contracting by 8.8%, the company's revenue is still expected to outpace the Norwegian market, growing at 9.4% annually compared to the market's 2.6%. This resilience is further highlighted by Atea's recent dividend affirmation, committing NOK 786 million back to shareholders, showcasing confidence in its financial health and ongoing value creation strategies. Dive into the specifics of Atea here with our thorough health report. Examine Atea's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Paradox Interactive AB (publ) is a company that focuses on developing and publishing strategy and management games for PC and consoles across various global regions, with a market cap of approximately SEK20.90 billion. Operations: The company generates revenue primarily from its Computer Graphics segment, amounting to SEK2.18 billion. It operates in diverse regions including North and Latin America, Europe, the Middle East, Africa, and the Asia Pacific. Paradox Interactive, amidst a dynamic European tech landscape, continues to innovate and expand its gaming universe. The company's recent announcement of two new DLC packs for "Across the Obelisk" underscores its commitment to enhancing player experience and broadening content availability across multiple platforms. Strategic alliances like the one seen with Room 8 Group for "Crusader Kings III: Legacy of Persia" not only diversify Paradox's portfolio but also deepen its historical game narratives, reinforcing its niche in strategy games. Financially, Paradox is poised for growth with a revenue increase of 9.3% annually and an earnings forecast growing at 21.5% per year, complemented by a robust R&D investment strategy that ensures continuous innovation and competitiveness in the high-stakes gaming market. Click here and access our complete health analysis report to understand the dynamics of Paradox Interactive. Gain insights into Paradox Interactive's historical performance by reviewing our past performance report. Take a closer look at our European High Growth Tech and AI Stocks list of 228 companies by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:ORY OB:ATEA and OM:PDX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
19-03-2025
- Business
- Yahoo
High Growth Tech Stocks In Europe March 2025
In March 2025, the European market is navigating a complex landscape characterized by concerns over U.S. trade tariffs, economic growth uncertainties, and fluctuating monetary policies. Despite these challenges, high growth tech stocks in Europe continue to attract attention as investors seek opportunities that align with resilient business models and innovative capabilities capable of weathering broader market volatility. Name Revenue Growth Earnings Growth Growth Rating Elicera Therapeutics 63.53% 97.24% ★★★★★★ Pharma Mar 24.24% 40.82% ★★★★★★ CD Projekt 30.55% 39.06% ★★★★★★ Yubico 20.88% 26.53% ★★★★★★ Xbrane Biopharma 73.73% 139.21% ★★★★★★ XTPL 97.45% 117.95% ★★★★★★ Devyser Diagnostics 26.50% 94.65% ★★★★★★ Elliptic Laboratories 49.76% 88.21% ★★★★★★ Ascelia Pharma 46.09% 66.93% ★★★★★★ Skolon 29.71% 91.18% ★★★★★★ Click here to see the full list of 243 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €228.43 million. Operations: Oryzon Genomics focuses on the discovery and development of epigenetics-based therapeutics targeting cancer and CNS disorders. As a clinical stage biopharmaceutical company, it does not currently report revenue from product sales. Oryzon Genomics is making significant strides in the biotech sector, particularly in precision medicine for psychiatric and neurodevelopmental disorders. Recently, Oryzon announced positive outcomes from Phase IIa trials of vafidemstat in various psychiatric conditions and is advancing this promising drug into a Phase III trial for Borderline Personality Disorder, with FDA discussions set for the first half of 2025. This progression underscores Oryzon's commitment to addressing unmet medical needs through innovative therapies. Furthermore, the company's recent presentation at BIO-Europe Spring and its continuous R&D efforts highlight its potential to impact future treatments significantly. With an annual revenue growth forecast at 52% and earnings expected to surge by approximately 54%, Oryzon exemplifies a dynamic player within Europe's high-growth tech landscape. Navigate through the intricacies of Oryzon Genomics with our comprehensive health report here. Gain insights into Oryzon Genomics' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: BioGaia AB (publ) is a healthcare company that develops and sells probiotic products globally, with a market capitalization of SEK11.83 billion. Operations: The company generates revenue primarily from its Pediatrics segment, contributing SEK 1.09 billion, followed by the Adult Health segment at SEK 321.29 million. BioGaia, a Swedish biotech firm, has recently demonstrated robust financial performance with its Q4 sales surging by 23% to SEK 365 million and operating profit increasing by 28% to SEK 103 million. This growth is underpinned by an annual revenue increase of 10.9% and earnings growth forecasted at 15% per year, outpacing the Swedish market averages significantly. The company's strategic move to directly manage its operations in France reflects a proactive approach in tapping into the growing health-conscious consumer base there, leveraging its reputation for high-quality probiotics. These developments suggest BioGaia is effectively capitalizing on niche market trends while maintaining strong financial health. Click here to discover the nuances of BioGaia with our detailed analytical health report. Assess BioGaia's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Telefonaktiebolaget LM Ericsson (publ) is a company that offers mobile connectivity solutions to communications service providers, enterprises, and the public sector, with a market capitalization of approximately SEK278.13 billion. Operations: Ericsson generates revenue primarily from its Networks segment, which accounts for SEK158.21 billion, followed by Cloud Software and Services at SEK62.64 billion, and Enterprise at SEK24.86 billion. The company's business model focuses on providing mobile connectivity solutions to various sectors including communications service providers and enterprises. Telefonaktiebolaget LM Ericsson, a stalwart in telecommunications, is making significant strides in leveraging advanced technologies like AI and 5G. With its recent strategic alliances, including a notable partnership with Volvo Group and Bharti Airtel to explore Extended Reality and Digital Twin technologies, Ericsson is at the forefront of industrial digital transformation. This collaboration aims to enhance manufacturing processes and workforce training through the integration of 5G's ultra-low latency capabilities. Financially, Ericsson has demonstrated robust growth with a notable increase in earnings forecasted at an impressive 47% annually. Despite moderate revenue growth projections at 1.9% per year, the company's commitment to R&D remains strong, ensuring sustained innovation and competitiveness in the high-tech industry landscape. Dive into the specifics of Telefonaktiebolaget LM Ericsson here with our thorough health report. Review our historical performance report to gain insights into Telefonaktiebolaget LM Ericsson's's past performance. Click here to access our complete index of 243 European High Growth Tech and AI Stocks. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:ORY OM:BIOG B and OM:ERIC B. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
19-03-2025
- Business
- Yahoo
European Growth Companies With High Insider Ownership To Watch
As European markets navigate the complexities of U.S. trade tariffs and shifting monetary policies, the pan-European STOXX Europe 600 Index recently experienced a decline amid these uncertainties. In this environment, growth companies with high insider ownership can be particularly interesting to watch, as their leadership's vested interest may align with shareholder value creation during turbulent times. Name Insider Ownership Earnings Growth Elicera Therapeutics (OM:ELIC) 27.8% 97.2% Vow (OB:VOW) 13.1% 120.9% Pharma Mar (BME:PHM) 11.8% 40.8% CD Projekt (WSE:CDR) 29.7% 39.1% Bergen Carbon Solutions (OB:BCS) 12% 50.8% XTPL (WSE:XTP) 27.9% 118% Elliptic Laboratories (OB:ELABS) 22.6% 88.2% Nordic Halibut (OB:NOHAL) 29.8% 56.3% Ortoma (OM:ORT B) 27.7% 68.6% Circus (XTRA:CA1) 26% 51.4% Click here to see the full list of 229 stocks from our Fast Growing European Companies With High Insider Ownership screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €228.43 million. Operations: Oryzon Genomics S.A. generates revenue through the discovery and development of therapeutics targeting epigenetic mechanisms for cancer and central nervous system disorders. Insider Ownership: 10.3% Earnings Growth Forecast: 54% p.a. Oryzon Genomics, a European growth company with significant insider ownership, is advancing its clinical pipeline with promising developments in psychiatric and neurodegenerative disorders. Recent announcements highlight the progression of vafidemstat into Phase III trials for Borderline Personality Disorder (BPD) following positive Phase IIb results. Despite reporting a net loss of €3.67 million in 2024, Oryzon's revenue is forecast to grow substantially at 52% annually, outpacing the Spanish market significantly. Click here to discover the nuances of Oryzon Genomics with our detailed analytical future growth report. In light of our recent valuation report, it seems possible that Oryzon Genomics is trading beyond its estimated value. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Attendo AB (publ) operates by providing health and care services across Scandinavia and Finland, with a market cap of SEK9.56 billion. Operations: The company's revenue is primarily generated from its Care and Health Care Services segment, amounting to SEK18.98 billion. Insider Ownership: 15.6% Earnings Growth Forecast: 21.2% p.a. Attendo, a European growth company with substantial insider ownership, is trading well below its estimated fair value. Its earnings are forecast to grow significantly at 21.22% annually, surpassing the Swedish market's growth rate. Despite slower revenue growth at 4% annually, recent financials show improved performance with Q4 sales rising to SEK 4.88 billion and net income doubling year-over-year to SEK 108 million. Leadership changes include Malin Fredgardh Huber as Business Area Director for Scandinavia. Click to explore a detailed breakdown of our findings in Attendo's earnings growth report. Our valuation report unveils the possibility Attendo's shares may be trading at a discount. Simply Wall St Growth Rating: ★★★★★☆ Overview: Init innovation in traffic systems SE, along with its subsidiaries, provides intelligent transportation systems solutions for public transportation globally, with a market cap of €401.96 million. Operations: The company's revenue is primarily derived from its Wireless Communications Equipment segment, which generated €245.89 million. Insider Ownership: 39.6% Earnings Growth Forecast: 27.8% p.a. init innovation in traffic systems, a European growth company with substantial insider ownership, is trading at good value compared to its peers and industry. While revenue is forecast to grow at 12.3% annually, slower than the 20% benchmark yet faster than the German market's 5.9%, earnings are expected to rise significantly by 27.78% per year, outpacing the German market's growth rate of 16.4%. Return on Equity is projected to be high at 21%. Click here and access our complete growth analysis report to understand the dynamics of init innovation in traffic systems. The valuation report we've compiled suggests that init innovation in traffic systems' current price could be quite moderate. Unlock our comprehensive list of 229 Fast Growing European Companies With High Insider Ownership by clicking here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include BME:ORY OM:ATT and XTRA:IXX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
27-01-2025
- Business
- Yahoo
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting
Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, scheduled for February 28. Four new members will be added to the Board: Dr. Konstantinos Alataris, Dr. Pierre Beaurang, Dr. Montserrat Vendrell, and Luis Sánchez Quintana. At the same time, in accordance with Spanish law, several independent directors are approaching the maximum tenure of 12 years. Consequently, the independent directors Ramón Adell, Isabel Aguilera and Antonio Fornieles will conclude their terms. Additionally, Mr. Josep Ma Echarri and Dr. Tamara Maes have announced their intention to step down. Mr. Echarri cited the accumulation of responsibilities across various public company boards as the reason for his decision, while Dr. Maes stated personal reasons not to stand for reelection. Meanwhile, Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain on the Board, subject to a positive vote by the Shareholders' Meeting. The company extends its sincere gratitude to each of the departing directors for their dedication and invaluable contributions throughout their tenure. Their unwavering commitment and professionalism have been pivotal to the company's growth and success. The company reaffirms its commitment to good corporate governance and transparency in all its actions. The renewal of the Board of Directors reflects this commitment and the company's determination to continue advancing the implementation of best practices for the benefit of all its shareholders and stakeholders. The company has conducted a rigorous selection process to appoint new independent directors who meet the highest standards of independence, experience, and industry knowledge. This expertise is crucial to the next phase of the company's development, where, with Phase 3 and Phase 2 assets, it must optimize its outreach to corporate partners and Tier-1 investors. The process has been conducted with the utmost transparency and in full compliance with applicable regulations. As a result, this process has culminated in the selection of a group of highly qualified candidates for their potential shareholder approval, as presented and described below: Dr. Konstantinos Alataris is an accomplished entrepreneur with over 30 years of experience in the United States. He specializes in scaling innovative medical technology companies and successfully commercializing novel therapeutics. With a strong background as a founder, CEO, investor, and board member in the medical device industry, Dr. Alataris brings invaluable expertise to his endeavors. Notable positions in his career include serving as the Founder, President, and CEO of Nevro Corp, as well as the CEO and Co-Founder of Nēsos and the President and CEO of Zosano Pharma. Additionally, Dr. Alataris has chaired the scientific advisory board of iota Biosciences, which was acquired by Astellas Pharma. He has worked in various fields, including autoimmune, neurosurgical, neurological, neuropsychiatric, orthopedic, and cardiac disorders, both in operational roles and as a board member. Dr. Alataris holds a B.A. in Electrical and Electronics Engineering by the University of Athens, a PhD in Bioengineering & Biomedical Engineering by the University of Southern California and MBA in Finance by the University of Southern California. Dr. Pierre Beaurang brings over 25 years of experience in biotechnology, with a focus on corporate strategy, business development, oncology, immunology, and neurology. Most recently, Dr. Beaurang served as CEO of Nitrase Therapeutics, a private biotechnology company specializing in a novel class of enzymes associated with neurodegenerative disorders and cancer. Previously, he held the position of Chief Business Officer at Nurix Therapeutics, where he played a pivotal role in scaling the company into a publicly traded, clinical-stage enterprise. During his time at Nurix, Dr. Beaurang led the establishment of transformative partnerships with global pharmaceutical companies and was an integral part of the leadership team driving the company's successful IPO. Dr. Beaurang was also a founding member of Five Prime Therapeutics (later acquired by Amgen), an oncology and immunology biologics company. At Five Prime, he secured several major platform and product collaborations with pharmaceutical companies and licensed the company's lead asset, which ultimately resulted in its acquisition for $1.9 billion in 2021. Dr. Beaurang holds a B.A. in Biology and an M.A. in Biotechnology from Boston University, as well as a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. Luis Sánchez Quintana is a former Partner at PwC, bringing over 33 years of professional experience, including 17 years as a Partner. During his tenure, he held the prestigious role of Global Head of the Pharma and Life Sciences Sector, where he provided strategic guidance to numerous leading companies. Mr. Sánchez Quintana served as Audit Partner for Laboratorios Rovi, supporting its growth trajectory and eventual IPO, as well as for other listed companies in the Spanish pharmaceutical sector, including Pharmamar and Faes. His extensive portfolio also includes serving as Audit Partner for key subsidiaries of multinational groups such as MSD, BMS, AstraZeneca, Roche, Laboratorios Indas, Farmalíder, Teva, GSK, Janssen, Johnson & Johnson, Italfármaco, Unolab, and Grupo Alter, among others. Additionally, he played a critical role in Nasdaq matters, acting as the responsible partner for Tigenix and as coordinator and advisor for PwC during VectiBio's Nasdaq listing. With his extensive expertise in auditing and advising pharmaceutical and life sciences companies, Mr. Sánchez Quintana has been instrumental in supporting organizations through growth, regulatory, and financial milestones. Mr. Sánchez Quintana holds a Bachelor's Degree in Economics and Business Administration from the Complutense University of Madrid and a Master's in Economics and Business Management (Executive MBA) from IESE Business School (University of Navarra). Dr. Montserrat Vendrell is partner at Aliath bioventures, a Barcelona-based venture capital firm specializing in investments in life sciences companies. With a distinguished career spanning leadership roles in science and innovation, Dr. Vendrell previously served as CEO of Biocat (2007–2015), the Barcelona Science Park (2014–2015), and the Barcelona Institute of Science and Technology (BIST). Dr. Vendrell holds a Ph.D. in Biology from the University of Barcelona and conducted post-doctoral research at Hoffmann-La Roche in New Jersey, USA, as well as at the Spanish National Research Council (CSIC). She also earned a Master's in Scientific Communication from UPF-Barcelona School of Management and completed the General Management Program (PDG) at IESE Business School. In addition to her current role at Aliath bioventures, Dr. Vendrell serves as Chair of the Executive Committee of the Pasqual Maragall Foundation for Research in Alzheimer's Disease, reflecting her ongoing dedication to advancing biomedical innovation and research. She is also Board-Director at the following Biotech companies: Peptomyc, Ona Therapeutics, Inbrain Neuroelectronics, and Accure Therapeutics. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon's securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements. Spain Oryzon IR & Media, Europe & US Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid Atrevia Chief BD Officer LifeSci Advisors, LLC +34 91 564 07 25 +34 673 33 97 65 +34 93 515 1313 +41 78 680 05 38 pcobo@ mcordera@ etorrell@ svonderweid@
